FMC Corporation 2005 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: FMC Corporation
Reporting Period: Fiscal year ended December 31, 2005
Business Overview: FMC is a diversified, global chemical company operating in three segments: Agricultural Products (insecticides and herbicides), Specialty Chemicals (BioPolymer food/pharma ingredients and lithium), and Industrial Chemicals (soda ash, peroxygens, and phosphorus chemicals). The company spun off its machinery business (FMC Technologies) in 2001.
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Revenue | $2,150.2 million | $2,051.2 million |
| Net Income | $116.6 million | $160.2 million |
| Diluted EPS | $2.97 | $4.28 |
| Operating Cash Flow | $199.6 million | $239.0 million |
| Total Debt | $720.2 million | $929.6 million |
| Long-Term Debt | $639.8 million | $822.2 million |
| Cash and Equivalents | $206.4 million | $212.4 million |
| Interest Expense | $62.3 million | $80.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 5% to $2.15 billion, driven by growth in all segments. Industrial Chemicals grew 7% (higher soda ash prices), Specialty Chemicals grew 4% (lithium pricing), and Agricultural Products grew 3% (stronger sales in South America/Asia).
- Net Income Decline: Net income decreased 27% to $116.6 million. This decline was primarily due to a $60.5 million loss on extinguishment of debt (redemption of Senior Notes) and $40.4 million in restructuring charges, which offset higher operating profits and lower interest expense.
- Debt Reduction: Total debt decreased by approximately $209 million. The company redeemed $355 million of 10.25% Senior Notes and refinanced credit agreements to lower interest costs and improve liquidity.
- One-Time Gains: The company recorded a $57.7 million pre-tax gain from the sale of substantially all assets of its 50% joint venture, Astaris (now Siratsa), and a $9.3 million gain from the sale of its investment in Sibelco.
- Restructuring: Charges of $40.4 million were recorded in 2005, including plant closures in Copenhagen and Bezons, and abandonment of assets in West Virginia and Idaho.
Guidance, Outlook, and Risks
- 2006 Outlook: Management expects continued earnings growth driven by higher selling prices in Industrial Chemicals (30-35% earnings growth expected) and lower interest expense. Agricultural Products revenue is expected to be flat, while Specialty Chemicals revenue is expected to grow low-to-mid single digits.
- Capital Allocation: The Board authorized a $150 million share repurchase program and initiated a quarterly cash dividend of $0.18 per share (first dividend since 2003).
- Environmental Liabilities: Total environmental reserves were $170.4 million (net of recoveries). Management estimates reasonably possible loss contingencies may exceed accrued amounts by up to $85 million. Projected 2006 environmental spending is approximately $60 million.
- Key Risks:
- Regulatory: Antitrust investigations regarding hydrogen peroxide in Europe and the U.S., and microcrystalline cellulose.
- Market: Sensitivity to raw material and energy costs; foreign exchange fluctuations (Euro, Brazilian Real).
- Operational: Capacity utilization in Industrial Chemicals and competition from generic producers in Agricultural Products.
Investor Verification Checklist
- Debt Refinancing Impact: Verify the sustainability of lower interest costs following the redemption of high-coupon Senior Notes and the terms of the new Domestic and European Credit Agreements.
- Environmental Reserves: Assess the adequacy of the $170.4 million reserve against the $85 million potential additional exposure, specifically regarding the Pocatello, Idaho site and New Jersey NPL sites.
- Antitrust Exposure: Monitor the status of the European Commission and U.S. Department of Justice investigations into hydrogen peroxide pricing and the microcrystalline cellulose class action.
- Astaris Divestiture: Confirm the final working capital adjustments and the realization of the $99.4 million cash proceeds from the Astaris asset sale.
- Segment Margins: Analyze the ability of the Agricultural Products segment to maintain margins amidst generic competition (e.g., bifenthrin) and rising raw material costs.